Organization (Hospital)
Lahey Clinic
ClinicalTrials.gov lists Lahey Clinic as lead sponsor of 61 trials. It has 10 active development programs and 19 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Lahey Hospital & Medical Center, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Lahey Clinic: 61 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (93)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 5 |
| Hemorrhage | 4 |
| Urinary Bladder Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
| Liver Neoplasms | 3 |
Showing 5 of 93 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2023 | 2 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
| 2015 | 5 |
| 2014 | 5 |
Showing 10 of 25 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Stereotactic Body Radiation Therapy | Carcinoma, Hepatocellular | Phase 3 | 2 |
| Stereotactic Body Radiation Therapy | Liver Neoplasms | Phase 3 | 2 |
| Trans-arterial chemoembolization (TACE) | Carcinoma, Hepatocellular | Phase 3 | 2 |
| Trans-arterial chemoembolization (TACE) | Liver Neoplasms | Phase 3 | 2 |
| Doxorubin | Carcinoma, Hepatocellular | Phase 3 | 2 |
Showing 5 of 10 active programs.
Approved assets (19)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Nasopore Stent and either Gentamycin or Bacitracin | 1 |
| 0.5% Bupivicaine | 1 |
| Regional Anesthesia | 1 |
| Long-Acting Local Anesthesia | 1 |
| Merogel Nasal Stent and Nasopore Stent | 1 |
Showing 5 of 19 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 32% hit target (n=19) | 25% on time (n=16) |
Journals published in (146)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of urology | 15 |
| The New England journal of medicine | 15 |
| Journal of the American College of Cardiology | 10 |
| Circulation | 7 |
| Urology | 7 |
Showing 5 of 146 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 11 | 4 | 2025-07-15 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2020-07-13 | NIH grant | 77,450 | Reporter |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Varian Medical Systems (United States) | Co sponsors trial with | 2 |
| Roche (Switzerland) | Co sponsors trial with | 1 |
| St. Louis University | Co sponsors trial with | 1 |
| Fondazione Serena Onlus - Centro Clinico NeMO Milano | Co sponsors trial with | 1 |
| Tel Aviv Medical Center | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (91)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-07-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-04-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-02-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 91 events.
CLIA clinical laboratory certificates (4)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| LAHEY HOSPITAL & MEDICAL CENTER | Certificate of accreditation | Active |
| LAHEY HOSPITAL AND MEDICAL CENTER | Certificate of registration | Active |
| LAHEY HOSPITAL & MEDICAL CENTER | Certificate of waiver | Active |
| LAHEY HOSPITAL & MEDICAL CENTER | Certificate of accreditation | Terminated |
Biomarker capability evidence (89)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| BCL2L10 | Trial sponsor | Named in trial inclusion criteria |
| CARD11 | Trial collaborator | Named in trial inclusion criteria |
| CD19 | Trial collaborator | Named in trial inclusion criteria |
| CD81 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 89 evidence rows.
Biomarkers this organization publishes on (111)
Shown in this order: most publications first.
Showing 5 of 111 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.